Evidence map›Paper›PMID 24466208›Full record

ArticlePloS one2014

Distinct and site-specific phosphorylation of the retinoblastoma protein at serine 612 in differentiated cells.

Takayuki Hattori, Chiharu Uchida, Hirotaka Takahashi, Naoki Yamamoto, Mikihiko Naito, Yoichi Taya

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Detection of Retinoblastoma Protein Phosphorylation by Immunoblot Analysis.Methods in molecular biology (Clifton, N.J.) · 2018
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Takayuki HattoriDivision of Biochemistry and Molecular Biology, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan ; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Chiharu UchidaCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore ; Research Equipment Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Hirotaka TakahashiDivision of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, Ehime, Japan ; Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Naoki YamamotoDepartment of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Mikihiko NaitoDivision of Biochemistry and Molecular Biology, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan.
Yoichi TayaCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore ; Department of Biochemistry, National University of Singapore, Singapore, Singapore.
National University of Singapore · SGNational Institute of Health Sciences · JPEhime University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The retinoblastoma susceptibility protein (pRB) is a phosphoprotein that regulates cell cycle progression at the G1/S transition. In quiescent and early G1 cells, pRB predominantly exists in the active hypophosphorylated form. The cyclin/cyclin-dependent protein kinase complexes phosphorylate pRB at the late G1 phase to inactivate pRB. This event leads to the dissociation and activation of E2F family transcriptional factors. At least 12 serine/threonine residues in pRB are phosphorylated in vivo. Although there have been many reports describing bulk phosphorylation of pRB, detail research describing the function of each phosphorylation site remains unknown. Besides its G1/S inhibitory function, pRB is involved in differentiation, prevention of cell death and control of tissue fate. To uncover the function of phosphorylation of pRB in various cellular conditions, we have been investigating phosphorylation of each serine/threonine residue in pRB with site-specific phospho-serine/threonine antibodies. Here we demonstrate that pRB is specifically phosphorylated at Ser612 in differentiated cells in a known kinase-independent manner. We also found that pRB phosphorylated at Ser612 still associates with E2F-1 and tightly binds to nuclear structures including chromatin. Moreover, expression of the Ser612Ala mutant pRB failed to induce differentiation. The findings suggest that phosphorylation of Ser612 provides a distinct function that differs from the function of phosphorylation of other serine/threonine residues in pRB.

Indexed as

Cell DifferentiationChromatinDNA-Binding ProteinsE2F1 Transcription FactorHumansK562 CellsNuclear ProteinsPhosphorylationRetinoblastoma ProteinSerineThreonineU937 CellsChromatinDNA-Binding ProteinsE2F1 protein, humanE2F1 Transcription FactorNuclear ProteinsRetinoblastoma ProteinSerineThreonine

Identifiers

PMID24466208
PMCPMC3897739
OpenAlexW1978793355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.